ALIGN TECHNOLOGY INC (ALGN)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for ALGN
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| ALGN | Director | 65 | ["Chief Innovation Officer, GE","CEO, GE Ventures and Licensing","General Partner, Mohr Davidow Ventures","Director and President, Affymetrix","Illumina, Inc.","The Engine","KFF","Nevro Corporation","National Venture Capital Association","Pacific Biosciences, Inc.","Tech Interactive","Affymetrix"] | ["Technology Committee","Nominating and Governance Committee"] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| ILMN | Board Chair at MIT The Engine; Director | 65 | ["Board Director at Align Technology","Board Director at the Kaiser Family Foundation","Senior Lecturer at MIT Sloan School of Management","Extensive experience leading and growing life science companies","Driving innovation","Knowledge of genomics markets and technology","Senior Lecturer, MIT Sloan School of Management","Chief Innovation Officer of General Electric (GE)","CEO of GE Business Innovations","General Partner, Mohr Davidow Ventures","President and Board Member of Affymetrix, Inc.","Sr. Executive, Amersham Pharmacia Biotech","Board Chair at MIT The Engine"] | ["Compensation (Chair)"] | 2026 |
Biography sourced from the proxy statement filing.
Age : 65 Director since: 2017 Roles: Independent Director Committees: Nominating and Governance Committee, Technology Committee Election Term: 2026-2027 Experience: 2017 - 2019 Chief Innovation Officer, GE (conglomerate company) 2012 - 2017 CEO, GE Ventures and Licensing (conglomerate company) Prior General Partner, Mohr Davidow Ventures (multidisciplinary investment firm; Ms. Siegel focused investments in personalized medicine, life sciences and digital health) Director and President, Affymetrix (genomics company) Other Board Positions Illumina, Inc. (2019-present) The Engine (2016-2020), Chair (2020-present) KFF (formerly Kaiser Family Foundation) (2019-present) Nevro Corporation (2020-2025) National Venture Capital Association (2012-2016) Pacific Biosciences, Inc. (2006-2013) Tech Interactive (2003-2007) Affymetrix (2000-2006) Notable Experience and Key Board Contributions Ms. Siegel brings extensive experience in identifying, funding, pioneering, and implementing industry-shifting innovations in the life sciences, biomedical research, and healthcare industries. Ms. Siegel led Affymetrix, one of the fastest growing genomics companies of its time. She led it from a pre-revenue startup to a multi-billion dollar publicly listed company that helped shape the emerging genomics industry, including addressing the bioethical issues of its day. Ms. Siegel has been recognized in Fortune s 34 Leaders Who Are Changing Health Care, as one of The 100 Most Influential Women in Silicon Valley, Fierce Biotech s Top 10 Women in Medical Devices, and was awarded the Lifetime Achievement Award by Global Corporate Venture in 2020. She is an Aspen Institute Henry Crown Fellow and is a featured Multiplier in the bestselling book: Multipliers: How the Best Leaders Make Everyone Smarter. Education B.S. in Biology from the University of Puerto Rico M.S. in Biochemistry and Molecular Biology from Boston University Medical School